Company intelligence / Profile preview
Stelexis Therapeutics
New York, NY, United Statesstelexis.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Stelexis Therapeutics is developing therapies that selectively target pre-cancerous and cancer stem cells, aiming to address the root cause of tumor progression. Their TumorOrigin™ platform has enabled identification of novel druggable targets. Lead programs are in early development; no published clinical results yet[1][4].
- Therapeutic areas
- OncologyHematology
- Modalities
- Monoclonal antibodiesBiological products[3][4]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Deerfield Management Company (sole funder/investor)[2][5](No major pharma partnerships publicly disclosed.)
Beyond the preview
Go deeper on Stelexis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stelexis Therapeutics.